#!/usr/bin/env python3
"""
Updated Economic Comparison with Correct Pricing
Shows how 8mg is now CHEAPER than 2mg due to strategic pricing
"""

def show_updated_economics():
    """Display the dramatic change in economics with correct pricing."""
    
    print("\n" + "="*80)
    print("AFLIBERCEPT PRICING UPDATE - ECONOMIC IMPACT")
    print("="*80)
    
    # Pricing comparison
    print("\nðŸ’Š DRUG PRICING (per injection)")
    print("-" * 60)
    print(f"{'Product':<25} {'List Price':<15} {'NHS Price':<15} {'Discount':<15}")
    print(f"{'Aflibercept 2mg':<25} {'Â£816':<15} {'Â£457':<15} {'44% off':<15}")
    print(f"{'Aflibercept 8mg':<25} {'Â£998':<15} {'Â£339':<15} {'66% off':<15}")
    print(f"{'Biosimilar (est)':<25} {'Â£400':<15} {'Â£229':<15} {'43% off':<15}")
    print(f"\n{'KEY FINDING:':<25} {'8mg is Â£118 CHEAPER per injection than 2mg!'}")
    
    # Annual cost comparison
    print("\nðŸ“Š ANNUAL COST COMPARISON (Drug + Procedure costs)")
    print("-" * 80)
    print(f"{'Protocol':<30} {'Injections/yr':<15} {'Drug Cost':<15} {'Total Cost':<15} {'vs 2mg T&E':<15}")
    print(f"{'Treat & Extend 2mg':<30} {'6.9':<15} {'Â£3,153':<15} {'Â£6,582':<15} {'--':<15}")
    print(f"{'Treat & Extend 8mg':<30} {'6.1':<15} {'Â£2,068':<15} {'Â£5,100':<15} {'SAVES Â£1,482':<15}")
    print(f"{'Treat & Treat 2mg':<30} {'6.5':<15} {'Â£2,971':<15} {'Â£6,084':<15} {'SAVES Â£498':<15}")
    print(f"{'Biosimilar T&E':<30} {'6.9':<15} {'Â£1,580':<15} {'Â£5,009':<15} {'SAVES Â£1,573':<15}")
    
    # Strategic implications
    print("\nðŸŽ¯ STRATEGIC IMPLICATIONS")
    print("-" * 60)
    print("1. Eylea 8mg is now the CHEAPEST branded option")
    print("2. Only biosimilars will be cheaper (by just Â£91/year)")
    print("3. Complete reversal of previous economic analysis")
    print("4. No QALY justification needed - 8mg SAVES money")
    
    # Budget impact
    print("\nðŸ’° NHS BUDGET IMPACT")
    print("-" * 60)
    print("If 28,000 patients switch from 2mg to 8mg:")
    print(f"  â€¢ Annual savings: Â£41.5 million")
    print(f"  â€¢ Per CCG (assuming 200 CCGs): Â£207,500 saved")
    print(f"  â€¢ Plus capacity savings from fewer visits")
    
    # Decision matrix
    print("\nðŸ“‹ UPDATED DECISION MATRIX")
    print("-" * 60)
    print("Clinical Need                    Recommended Option           Rationale")
    print("-" * 80)
    print("New to treatment                 Eylea 8mg                   Lowest cost + best intervals")
    print("Stable on 2mg                    Switch to 8mg               Save money + reduce visits")
    print("Cost minimization only           Biosimilar when available   Cheapest option")
    print("Extended intervals crucial       Eylea 8mg                   Best interval maintenance")
    
    # Timeline considerations
    print("\nâ° TIMING CONSIDERATIONS")
    print("-" * 60)
    print("â€¢ Current window: 8mg priced to gain market share")
    print("â€¢ Biosimilar entry: Will disrupt 2mg market")
    print("â€¢ Strategic opportunity: Lock in 8mg before biosimilar launch")
    print("â€¢ Price risk: 8mg discount may reduce post-biosimilar")
    
    print("\n" + "="*80)
    print("CONCLUSION: Eylea 8mg has transformed from premium product to cost-saving option")
    print("="*80)

if __name__ == "__main__":
    show_updated_economics()